IN THIS XERFI GLOBAL REPORT :
WHAT IS THE GROUP'S FINANCIAL SITUATION ?
The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.
WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?
Sustain strength of pharmaceutical pipeline through innovation
Create smart, less invasive solutions to drive Medtech growth
Divest Consumer Health business
WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?
Through a SWOT analysis, this report also provides an overview of the group's strengths (strong innovation pipeline and one of the biggest R&D budgets in the industry, etc.) and weaknesses (lacklustre organic performance of Medtech portfolio, etc.).